Viatris has lagged the broader Nasdaq Composite over the past year, and Wall Street sentiment toward the stock remains ...

Viatris faces declining sales and debt concerns, but a 2026 recovery may boost earnings. Read about the key risks and future ...

In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Viatris Inc. is one of them. Viatris Inc. (NASDAQ:VTRS), formed from the 2020 merger of Mylan ...

In this article, we will be taking a look at the 12 Cheap Healthcare Stocks to Buy Now. Viatris Inc. is one of them. Viatris Inc. (NASDAQ:VTRS), a global healthcare company formed from the 2020 merger ...

Viatris Inc. (VTRS) delivered second-quarter 2025 adjusted earnings of 62 cents per share, which beat the Zacks Consensus Estimate of 56 cents. The company recorded adjusted earnings of 69 cents per ...

This was the stock's sixth consecutive day of losses.

NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the ...

The company reports under four segments on the basis of geography — Developed Markets; Emerging Markets; Japan, Australia and New Zealand (“JANZ”); and Greater China. Growth in Developed Markets, ...

Aug 7 (Reuters) - Drugmaker Viatris (VTRS.O), opens new tab beat Wall Street estimates for second-quarter profit and revenue on Thursday, helped by demand for its products in China, sending its shares ...

Viatris Inc. closed 29.96% below its 52-week high of $13.55, which the company achieved on November 25th.